A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis
Latest Information Update: 25 Aug 2023
At a glance
- Drugs GSK 2982772 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 14 Nov 2018 Status changed from active, no longer recruiting to completed.
- 28 Oct 2018 This trial has been completed in Spain (End date: 2018-10-22).
- 06 Oct 2018 This trial has been completed in Germany.